糖尿病性胃不全麻痺治療の世界市場-2023-2030年

概要

糖尿病性胃不全麻痺治療の世界市場は、2022年に31億米ドルに達し、2023-2030年の予測期間中にCAGR 3.8％で成長し、2030年までに42億米ドルに達すると予想されます。個々の疾患特性に特化した治療を可能にする個別化医療へのシフトのような動向は、世界の糖尿病性胃不全麻痺治療市場を独占すると予想されます。

さらに、糖尿病有病率の上昇、世界の老人人口の増加、診断技術や治療法の進歩、臨床試験の増加などが糖尿病性胃不全麻痺治療市場規模を押し上げています。

糖尿病性胃不全麻痺治療のアプローチを用いた疾患治療のための研究活動の増加や、確立された製薬会社の存在は、北米地域からの需要の要因の一部です。その他の競合としては、EVOKE PHARMA、ANI Pharmaceuticals, Inc.、Janssen Pharmaceutica N.V.などが挙げられます。

ダイナミクス

高齢者人口の増加が糖尿病性胃不全麻痺治療薬市場の成長を牽引

高齢者人口の増加は、世界の糖尿病性胃不全麻痺市場の大きな原動力となっています。糖尿病は高齢者人口に蔓延しつつあり、そのため胃下垂症例が増加しています。例えば、世界保健機関（WHO）の2022年報告書によると、2030年までに世界の6人に1人が60歳以上になるとされています。この時点で、60歳以上の人口は2020年の10億人から14億人に増加します。

さらに2050年には、世界の60歳以上の人口は倍増する（21億人）。2020年から2050年の間に、80歳以上の人口は3倍に増え、4,260億人に達すると予想されています。このような加齢に伴うリスクは、糖尿病性胃不全麻痺の診断ツール、治療法、療法に対する需要に大きく寄与しています。したがって、高齢者人口が増加するにつれて、糖尿病性胃不全麻痺治療の市場は予測期間中に成長すると予想されます。

新しい治療法の出現が糖尿病性胃不全麻痺治療市場の成長を促進する

新たな治療法の出現が糖尿病性胃不全麻痺治療を牽引すると予測されます。胃排出を改善するために胃の筋肉を刺激するよう特別に設計された薬剤もあります。リラモレリン、プルカロプリド、アプレピタントは、3つの有望な実験的薬理学的医薬品です。リラモレリンは合成ペンタペプチドグレリン受容体作動薬であり、2型糖尿病患者において胃排出遅延を示しながら、確実な胃排出を増加させることが証明されています。

例えば、運動促進薬は胃排出の改善を助けることができます。研究者は、開発中の新薬であるVelusetragなど、胃不全麻痺を治療する新規薬剤を探し続けています。さらに、Evoke Pharmaは2020年、急性および再発性の糖尿病性胃不全麻痺患者の症状を治療するGimoti点鼻スプレーの新薬申請をFDAが承認したと発表しました。このように、上記の要因によって、市場は予測期間中に牽引すると予想されます。

糖尿病性胃不全麻痺治療のためのFDA承認治療薬の欠如は、市場の成長を妨げると思われます。

糖尿病性胃不全麻痺の治療または管理を特に意図したFDA承認薬の欠如は、市場の拡大を大きく妨げます。この規制上の障壁は、承認され標準化された医薬品の入手を制限し、糖尿病性胃不全麻痺患者の治療選択肢を減少させます。

例えば、現在FDAに承認されている胃不全麻痺治療薬はメトクロプラミドのみです。しかし、メトクロプラミドは糖尿病性胃不全麻痺に特別に承認されているのではなく、胃不全麻痺一般に承認されていることを理解する必要があります。ドンペリドンのような他の薬も胃不全麻痺の治療に有望ですが、この特定の病気に対してはFDAの承認を受けていません。したがって、上記の要因により、市場は当面抑制要因に直面すると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 老年人口の増加
    • 新しい治療法の出現
  • 抑制要因
    • 糖尿病性胃不全麻痺治療のためのFDA承認治療薬の欠如
  • 機会
    • 個別化医療への需要の高まり
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 COVID-19分析

第7章 タイプ別

• グレード2
• グレード3

第8章 薬剤クラス別

• 消化管運動機能改善薬
• 制吐剤
• 抗ヒスタミン薬
• その他

第9章 投与経路別

• 経口
• 非経口
• 経鼻

第10章 流通チャネル別

• 病院
• 小売薬局
• オンライン薬局

第11章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ

第12章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第13章 企業プロファイル

• EVOKE PHARMA
  • 企業概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な動向
• ANI Pharmaceuticals, Inc.
• Janssen Pharmaceutica N.V
• Teva Pharmaceuticals Inc.
• Pfizer Inc.
• Salix Pharmaceuticals, Inc.
• Allergan
• Novartis AG
• SCHWITZ BIOTECH
• Wellona Pharma

第14章 付録

Overview

Global Diabetic Gastroparesis Treatment Market reached US$ 3.1 billion in 2022 and is expected to reach US$ 4.2 billion by 2030 growing with a CAGR of 3.8% during the forecast period 2023-2030. The trend such as the shift towards personalized medicine enabling individual disease characteristics specific treatment is expected to dominate the global diabetic gastroparesis treatment market.

Furthermore, the rising prevalence of diabetes, increasing geriatric population around the globe, advancements in diagnostic technologies and treatment, and increasing number of clinical trials are driving up the diabetic gastroparesis treatment market size.

The growing research activities for treating disease using diabetic gastroparesis treatment approach and presence of establish pharmaceutical companies are some of the factors in demand from North America regions. With significant competitors EVOKE PHARMA, ANI Pharmaceuticals, Inc., Janssen Pharmaceutica N.V, and others actively operating in the market.

Dynamics

The Increasing Number of Geriatric Population to Drive the Growth of the Diabetic Gastroparesis Treatment Market

The growing elderly population is a major driving force in the worldwide diabetic gastroparesis market. Diabetes is becoming more prevalent in older population, thus leading gastroparesis cases. For instance, according to World Health Organization 2022 report, 1 out of 6 people in the world will be aged 60 years or over by 2030. At this point, the population aged 60 and up will climb from 1 billion in 2020 to 1.4 billion.

Moreover by 2050, the world's population of persons aged 60 and up will have doubled (2.1 billion). Between 2020 and 2050, the number of people aged 80 and more is expected to treble, reaching 426 Billion. This age-associated risk significantly contributes to the demand for diagnostic tools, treatments, and therapies for diabetic gastroparesis. Thus, as the geriatic population nmuber is expected to grow the market for diabetic gastroparesis treatment will drive over the forecast period.

The Emergence of New Therapies will Drive the Diabetic Gastroparesis Treatment Market Growth

Emerging therapies are predicted to drive diabetic gastroparesis treatment. There are various drugs available to treat gastroparesis, some of which are specially designed to stimulate the stomach muscles in order to improve gastric emptying. Relamorelin, prucalopride, and aprepitant are three promising experimental pharmacologic medicines. Relamorelin is a synthetic pentapeptide ghrelin receptor agonist that has been demonstrated to increase solid gastric emptying in type 2 diabetes patients while also demonstrating delayed gastric emptying.

Prokinetic drugs, for example, can aid improve stomach emptying. Researchers are continuing to look for novel drugs to treat gastroparesis, such as Velusetrag, a new drug under development. Furthermore, Evoke Pharma stated in 2020 that the FDA approved a new medication application for Gimoti nasal spray to treat symptoms in people with acute and recurrent diabetic gastroparesis. Thus, owing to the above factors the market is expected to drive over the forecast period.

The Lack of FDA Approved Therapies for Diabetic Gastroparesis Treatment Will Hamper the Growth of the Market.

The lack of FDA-approved medications specifically intended for the treatment or management of diabetic gastroparesis hampers market expansion significantly. This regulatory barrier restricts the availability of approved and standardized medicines, reducing treatment options for diabetic gastroparesis patients.

For instance, currently metoclopramide is the only FDA approved drug to treat gastroparesis . However, it is necessary to understand that metoclopramide is not approved specifically for diabetic gastroparesis, but rather for gastroparesis in general. Other drugs, such as domperidone, have showed promise in treating gastroparesis but are not FDA-approved for this specific illness. Thus, owing to the above factors the market is expected to face a restraint over the foreseeable future.

Segment Analysis

The global diabetic gastroparesis treatment market is segmented based on type, drug class, route of administration, distribution channel, and region.

Owing to the Better Effectiveness, the Gastroprokinetic Agents Segment Accounted for Approximately 34.6% of the Diabetic Gastroparesis Treatment Market Share

The gastroprokinetic agents segment is poised to dominate the diabetic gastroparesis treatment market due to effectiveness in enhancing the gastrointestinal motility and are used to treat gastroparesis. Metoclopramide a dopamine-2 (D2) receptors antagonist is the treatment of choice for gastroparesis, despite not being FDA approved for diabetic gastroparesis specifically, but it is still considered to be first line drug for treatment. In most countries, only two medications are approved or available for the treatment of gastroparesis are metoclopramide and domperidone.

Furthermore, the increasing number of clinical trial for treating diabetic gastroparesis employing gastroprokinetic agents is increasing. For instance, CinDome Pharma, Inc. is conducting a clinical trial to evaluate to evaluate the efficacy and safety of CIN-102 (Deudomperidone) in adults with diabetic gastroparesis. Currently the trial is in phase 2 and the estimated completion date for the trial is October 2024. Thus, due to gastroprokinetic agents better effectiveness the segment is expected to dominate over the forecast period.

Geographical Penetration

North America Accounted for Approximately 36.9% of the Market Share in 2022, Owing to the Rising Prevalence of Diabetes

North America, particularly the U.S., dominates the global diabetic gastroparesis treatment market due to presence of huge number of key players settled in the region, growing prevalence of diabetes, and high research activities along with developments of new therapies by major organization in the region.

The rising prevalence of diabetes is a major driver of the global diabetic gastroparesis market. As the number of people diagnosed with diabetes rises, it also increases the risk of diabetic gastroparesis. As in diabetic gastroparesis, hyperglycemia can affect stomach muscles and nerves of the interstitial cells of Cajal, which assist stomach muscles move.

For instance, according to American Diabetes Association report of 2022, approximately 37.3 Billion Americans, or 11.3% of the population had diabetes in 2019. About 283,000 people aging below 20 were diagnosed with diabetes in America. Furthermore, every year 1.4 Billion Americans are diagnosed with diabetes. Thus, owing to above factors the region is expected to grow over the forecast period.

Competitive Landscape

The major global players in the diabetic gastroparesis treatment market include: EVOKE PHARMA, ANI Pharmaceuticals, Inc., Janssen Pharmaceutica N.V, Teva Pharmaceuticals Inc., Pfizer Inc., Salix Pharmaceuticals, Inc., Allergan, Novartis AG, SCHWITZ BIOTECH, Wellona Pharma, and among others.

COVID-19 Impact Analysis

The impact of COVID-19 on the global diabetic gastroparesis treatment market is significant. COVID-19, a condition caused by infection with the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), commonly appears as fever, cough, and shortness of breath. After experiencing gastrointestinal (GI) symptoms alone or in conjunction with lung symptoms, some patients tested positive for SARS-CoV-2.

This could be due to GI SARS-CoV-2 infection or a systemic effect of the respiratory viral illness. COVID-19 can appear as a flare of their underlying GI condition in individuals with chronic GI illnesses such as gastroparesis, as viruses have historically been involved in exacerbations of chronic GI disorders such as gastroparesis. Thereby creating a major impact on the diabetic gastroparesis treatment market.

By Type

• Grade 2
• Grade 3

By Drug Class

• Gastroprokinetic Agents
• Antiemetic Agents
• Anti-histamines
• Others

By Route of Administration

• Oral
• Parenteral
• Nasal

By Distribution Channel

• Hospitals
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• On October 26, 2020, Evoke Pharma, Inc., a specialty pharmaceutical company dedicated to GI disease treatments, and EVERSANA, a leading provider of global commercial services to the life science industry, are pleased to announce the commercial launch of Gimoti (metoclopramide) nasal spray for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.

DMI Opinion

The Global Diabetic Gastroparesis Treatment Market is predicted to expand over the forecast period. It is defined by current trends toward personalized therapy adapted to specific disease characteristics. This market transformation is aided by the emergence of novel technologies such as CRISPR-Cas9 and RNA interference, as well as factors such as rising diabetes prevalence, a growing geriatric population, advancements in diagnostics and treatments, and increased clinical trials.

The presence of established pharmaceutical corporations and significant competitors, particularly in North America, drives the market, along with the growing elderly population. However, the lack of FDA-approved medicines for diabetic gastroparesis treatment remains a limitation. Because of its effectiveness in improving gastrointestinal motility, the Gastroprokinetic Agents segment is expected to grow. The COVID-19 pandemic has also had major effects on the market, with GI symptoms developing as part of the disease and potentially affecting underlying diseases such as gastroparesis. Overall, the market has the potential for growth as a result of these distinct dynamics and trends.

Why Purchase the Report?

• To visualize the global diabetic gastroparesis treatment market segmentation based on type, drug class, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of diabetic gastroparesis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.

The global diabetic gastroparesis treatment market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Drug Class
• 3.3. Snippet by Route of Administration
• 3.4. Snippet by Distribution Channel
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. The Increasing Number of Geriatric Population
    • 4.1.1.2. The Emergence of New Therapies
  • 4.1.2. Restraints
    • 4.1.2.1. The Lack of FDA Approved Therapies for Diabetic Gastroparesis Treatment
  • 4.1.3. Opportunity
    • 4.1.3.1. Increasing Demand for Personalized Medicine
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. Grade 2*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Grade 3

8. By Drug Class

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.1.2. Market Attractiveness Index, By Drug Class
• 8.2. Gastroprokinetic Agents*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Antiemetic Agents
• 8.4. Anti-histamines
• 8.5. Others

9. By Route of Administration

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.1.2. Market Attractiveness Index, By Route of Administration
• 9.2. Oral*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Parenteral
• 9.4. Nasal

10. By Distribution Channel

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.1.2. Market Attractiveness Index, By Distribution Channel
• 10.2. Hospitals*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Retail Pharmacies
• 10.4. Online Pharmacies

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.7.1. U.S.
    • 11.2.7.2. Canada
    • 11.2.7.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.7.1. Germany
    • 11.3.7.2. U.K.
    • 11.3.7.3. France
    • 11.3.7.4. Spain
    • 11.3.7.5. Italy
    • 11.3.7.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.7.1. Brazil
    • 11.4.7.2. Argentina
    • 11.4.7.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.7.1. China
    • 11.5.7.2. India
    • 11.5.7.3. Japan
    • 11.5.7.4. Australia
    • 11.5.7.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. EVOKE PHARMA*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. ANI Pharmaceuticals, Inc.
• 13.3. Janssen Pharmaceutica N.V
• 13.4. Teva Pharmaceuticals Inc.
• 13.5. Pfizer Inc.
• 13.6. Salix Pharmaceuticals, Inc.
• 13.7. Allergan
• 13.8. Novartis AG
• 13.9. SCHWITZ BIOTECH
• 13.10. Wellona Pharma

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us